FLNA on Nasdaq

FILANA THERAPEUTICS, INC.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerFLNA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAustin, Texas1
  • Incorporated inDE2
  • Business address6801 N Capital Of Texas Highway, Building 1; Suite 300, Austin, Tx 787312
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC. Our lead therapeutic drug candidate, simufilam, was under clinical evaluation for the proposed treatment of Alzheimer’s disease in two Phase 3 clinical studies through 2024, when all ongoing clinical trials for simufilam in Alzheimer’s disease were discontinued. The phase out of the Company’s Alzheimer's disease development program was completed in the second quarter…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$95.4M in 2025+1824% since 2019
-$150.0M-$100.0M-$50.0M02019: -$5.0M-$5.0M20192020: -$6.4M-$6.4M2020+30%2021: -$32.9M-$32.9M2021+410%2022: -$80.0M-$80.0M2022+143%2023: -$106.0M-$106.0M2023+32%2024: -$141.4M-$141.4M2024+33%2025: -$95.4M-$95.4M2025−33%
Net income45678-$91.0M in 2025+1864% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$4.6M-$4.6M20192020: -$6.3M-$6.3M2020+37%2021: -$32.4M-$32.4M2021+411%2022: -$76.2M-$76.2M2022+135%2023: -$97.2M-$97.2M2023+28%2024: -$24.3M-$24.3M2024−75%2025: -$91.0M-$91.0M2025+274%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Research and development$26.6M$69.6M$89.4M
General and administrative$68.8M$71.8M$16.5M
Total operating expenses$95.4M$141.4M$106.0M
Operating loss-$95.4M-$141.4M-$106.0M
Interest income$4.6M$8.5M$7.8M
Other income (loss), net-$203.0K$411.0K$907.0K
Gain from change in fair value of warrant liabilities$0$108.2M$0
Shares used in computing net loss per share, basic (in shares)48.3M shares46.3M shares41.9M shares
Net loss per share, basic (in dollars per share)-$1.88-$0.53-$2.32
Net loss-$91.0M-$24.3M-$97.2M
Adjustment for change in fair value of warrant liabilities$0-$43.8M$0
Adjusted numerator, diluted-$91.0M-$68.1M-$97.2M
Shares used in computing net loss per share, diluted (in shares)48.3M shares46.6M shares41.9M shares
Net loss per share, diluted (in dollars per share)-$1.88-$1.46-$2.32

Compare FILANA THERAPEUTICS, INC. with another company

Leadership

Who has led FILANA THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Remi Barbier2006–2024

Chair

  1. Remi Barbier2009–2018

President

  1. Remi Barbier2006–2024

Chief financial officer

  1. Peter S. Roddy2006–2016
  2. Eric Schoen2018–now

Chief operating officer

  1. Nadav Friedmann2006–2016
  2. Robert Christopher Cook2025–now
2010201520202025
Board members and other officers (20)

Former names

  • CASSAVA SCIENCES INCDec 21, 2018 to Feb 19, 20262
  • PAIN THERAPEUTICS INCJul 24, 2000 to Mar 25, 20192

Timeline

  1. Feb 7, 2006New chief executive Remi Barbier becomes CEO13

Filings

227 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 77 major events, 87 insider forms, 13 large holders, 30 other. The latest 20:

  1. Oct 1, 20264 EDGAR
  2. Sep 30, 20264 EDGAR
  3. Sep 22, 20268-K EDGAR
  4. Sep 18, 20268-K EDGAR
  5. Jul 29, 202610-Q EDGAR
  6. Jul 29, 20268-K EDGAR
  7. Jun 15, 20268-K EDGAR
  8. May 7, 202610-Q EDGAR
  9. May 7, 20268-K EDGAR
  10. Apr 28, 2026ARS EDGAR
  11. Apr 28, 2026DEF 14A EDGAR
  12. Apr 28, 20268-K EDGAR
  13. Mar 12, 202610-K EDGAR
  14. Mar 12, 20268-K EDGAR
  15. Mar 10, 20268-K EDGAR
  16. Feb 19, 20268-K EDGAR
  17. Dec 23, 20258-K EDGAR
  18. Dec 22, 20258-K/A EDGAR
  19. Dec 18, 20258-K EDGAR
  20. Dec 17, 20258-K EDGAR

The 227 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 17 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Barry RichardPresident & CEOBuy93,091$0.84$78.2KForm 4
Nov 24, 2025Anderson Robert Eugene JrDirectorBuy8,600$2.90$24.9KForm 4
Nov 20, 2025Barry RichardPresident & CEOBuy150,000$2.76$414.0KForm 4
Nov 19, 2025Barry RichardPresident & CEOBuy73,385$2.75$201.8KForm 4
Sep 30, 2025Cook Robert ChristopherChief Operating & Legal OfficeBuy13,725$2.91$39.9KForm 4
Sep 22, 2025Barry RichardPresident & CEOBuy7,172$2.28$16.4KForm 4
Sep 19, 2025Barry RichardPresident & CEOBuy47,308$2.29$108.3KForm 4
Sep 18, 2025Barry RichardPresident & CEOBuy190,633$2.24$426.4KForm 4
Nov 29, 2024Kupiec James WilliamChief Medical OfficerSale4,000$3.87$15.5KForm 4
Nov 29, 2024Schoen EricChief Financial OfficerSale61,800$3.86$238.5KForm 4
Aug 23, 2023ROBERTSON SANFORDDirectorBuy30,000$17.45$523.5KForm 4
Aug 22, 2023Barry RichardPresident & CEOBuy16,571$16.65$275.9KForm 4
Aug 21, 2023Barry RichardPresident & CEOBuy1,906$16.80$32.0KForm 4
Mar 7, 2023Barry RichardPresident & CEOBuy77,276$25.76$2.0MForm 4
Mar 6, 2023Barry RichardPresident & CEOBuy11,565$26.13$302.2KForm 4
Aug 23, 2022Barry RichardPresident & CEOBuy36,159$23.79$860.2KForm 4
Aug 23, 2022Kupiec James WilliamChief Medical OfficerBuy2,500$24.44$61.1KForm 4
Aug 12, 2022Schoen EricChief Financial OfficerBuy2,500$19.95$49.9KForm 4
Aug 12, 2022ROBERTSON SANFORDDirectorBuy100,000$20.69$2.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Jul 29, 202538
  • Matthew NachtrabSCHEDULE 13G/A, 2 filings Aug 21, 2024 to Nov 26, 202439
  • Remi BarbierSC 13G/A, 3 filings Feb 3, 2022 to Nov 4, 202440

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 84. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,974,981$2.4M0.0%+44,038
Two Sigma Investments, LP1,711,358$2.0M0.0%−277,456
Marshall Wace, Llp1,597,548$1.9M0.0%−414,995
BlackRock, Inc.1,453,561$1.7M0.0%+39,047
Goldman Sachs Group Inc668,792$795.9K0.0%+627,468
Geode Capital Management, LLC615,510$732.7K0.0%+19,268
D. E. Shaw & Co., Inc.485,025$577.2K0.0%−74,180
GMT Capital Corp450,100$535.6K0.0%No change
Renaissance Technologies LLC389,601$463.6K0.0%+62,842
Squarepoint Ops LLC318,380$378.9K0.0%New
Vanguard Fiduciary Trust Co315,889$375.9K0.0%+41,958
Susquehanna International Group, Llp292,017$347.5K0.0%−155,261
Group One Trading LLC244,008$290.4K0.0%−58,616
State Street Corp209,105$248.8K0.0%−30,882
Vanguard Portfolio Management LLC132,597$157.8K0.0%−96
Connor, Clark & Lunn Investment Management Ltd.132,298$157.4K0.0%−4,633
Federated Hermes, Inc.119,952$142.7K0.0%+4,855
Northern Trust Corp114,322$136.0K0.0%−34,872
Simplex Trading, LLC99,879$118.9K0.0%−40,116
Stifel Financial Corp75,000$89.2K0.0%New
XTX Topco Ltd64,614$76.9K0.0%+31,311
Jane Street Group, LLC58,981$70.2K0.0%−166,183
Verition Fund Management LLC46,870$55.8K0.0%+8,726
LPL Financial LLC40,172$47.8K0.0%−821
UBS Group AG39,062$46.5K0.0%+27,459

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40